The Efficacy of Lubiprostone in Patients of Constipation: An Updated Systematic Review and Meta‐Analysis

<h3>Background and Aim</h3><p dir="ltr">Lubiprostone increases chloride and water secretion in the intestines, and several studies have demonstrated the efficacy of lubiprostone in treating functional constipation. Several new clinical trials have emerged since the previo...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Umar Akram (20151411) (author)
مؤلفون آخرون: Obaid Ur Rehman (6555554) (author), Eeshal Fatima (18255772) (author), Zain Ali Nadeem (20487218) (author), Omer Usman (22282651) (author), Waqas Rasheed (7433984) (author), Ramsha Ali (22282654) (author), Khawaja Abdul Rehman (22282657) (author), Abdulqadir J. Nashwan (11659453) (author)
منشور في: 2025
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513539425697792
author Umar Akram (20151411)
author2 Obaid Ur Rehman (6555554)
Eeshal Fatima (18255772)
Zain Ali Nadeem (20487218)
Omer Usman (22282651)
Waqas Rasheed (7433984)
Ramsha Ali (22282654)
Khawaja Abdul Rehman (22282657)
Abdulqadir J. Nashwan (11659453)
author2_role author
author
author
author
author
author
author
author
author_facet Umar Akram (20151411)
Obaid Ur Rehman (6555554)
Eeshal Fatima (18255772)
Zain Ali Nadeem (20487218)
Omer Usman (22282651)
Waqas Rasheed (7433984)
Ramsha Ali (22282654)
Khawaja Abdul Rehman (22282657)
Abdulqadir J. Nashwan (11659453)
author_role author
dc.creator.none.fl_str_mv Umar Akram (20151411)
Obaid Ur Rehman (6555554)
Eeshal Fatima (18255772)
Zain Ali Nadeem (20487218)
Omer Usman (22282651)
Waqas Rasheed (7433984)
Ramsha Ali (22282654)
Khawaja Abdul Rehman (22282657)
Abdulqadir J. Nashwan (11659453)
dc.date.none.fl_str_mv 2025-01-15T09:00:00Z
dc.identifier.none.fl_str_mv 10.1002/jgh3.70070
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/The_Efficacy_of_Lubiprostone_in_Patients_of_Constipation_An_Updated_Systematic_Review_and_Meta_Analysis/30173347
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Biomedical and clinical sciences
Clinical sciences
Pharmacology and pharmaceutical sciences
chronic idiopathic constipation
constipation
irritable bowel syndrome
lubiprostone
opioid induced constipation
dc.title.none.fl_str_mv The Efficacy of Lubiprostone in Patients of Constipation: An Updated Systematic Review and Meta‐Analysis
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <h3>Background and Aim</h3><p dir="ltr">Lubiprostone increases chloride and water secretion in the intestines, and several studies have demonstrated the efficacy of lubiprostone in treating functional constipation. Several new clinical trials have emerged since the previous meta‐analysis conducted in 2020. We conducted this updated meta‐analysis to assess clinical efficacy of lubiprostone in these patients.</p><h3>Methods</h3><p dir="ltr">A systematic search was conducted on MEDLINE, Cochrane, and Scopus. Randomized controlled trials published between July 2019 and June 2024 were selected. Cochrane's RoB 2 tool was used to assess the risk of bias. A meta‐analysis was performed and findings were presented using forest plots.</p><h3>Results</h3><p dir="ltr">A total of 14 studies, comprising 4550 patients, were included in the review. Only 12 studies were pooled in the meta‐analysis. Lubiprostone was associated with greater spontaneous bowel movements (SBM) per week (RR 1.454, 95% CI 1.193–1.771) and SBM within 24 h (RR 1.790, 95% CI 1.491–2.150) in patients with chronic idiopathic constipation (CIC). However, it was not associated with abdominal pain in either arm (RR 1.415, 95% CI 0.873–2.294). In opioid‐induced constipation (OIC), lubiprostone increased SBM within 24 h (RR 1.277, 95% CI 1.105–1.475) but did not significantly affect abdominal pain (RR 4.321, 95% CI 0.624–29.941). Lubiprostone improved all selected SBM‐related and abdominal pain outcomes in patients with irritable bowel syndrome with constipation (IBS‐C).</p><h3>Conclusion</h3><p dir="ltr">Lubiprostone significantly improves all SBM‐related outcomes. Owing to its good safety and efficacy profile, lubiprostone can be used in the combination regimens for management of CIC, IBS‐C, and OIC.</p><h2>Other Information</h2><p dir="ltr">Published in: JGH Open<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/jgh3.70070" target="_blank">https://dx.doi.org/10.1002/jgh3.70070</a></p>
eu_rights_str_mv openAccess
id Manara2_b725b75dea42a0d397f240ffecd3eb97
identifier_str_mv 10.1002/jgh3.70070
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/30173347
publishDate 2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling The Efficacy of Lubiprostone in Patients of Constipation: An Updated Systematic Review and Meta‐AnalysisUmar Akram (20151411)Obaid Ur Rehman (6555554)Eeshal Fatima (18255772)Zain Ali Nadeem (20487218)Omer Usman (22282651)Waqas Rasheed (7433984)Ramsha Ali (22282654)Khawaja Abdul Rehman (22282657)Abdulqadir J. Nashwan (11659453)Biomedical and clinical sciencesClinical sciencesPharmacology and pharmaceutical scienceschronic idiopathic constipationconstipationirritable bowel syndromelubiprostoneopioid induced constipation<h3>Background and Aim</h3><p dir="ltr">Lubiprostone increases chloride and water secretion in the intestines, and several studies have demonstrated the efficacy of lubiprostone in treating functional constipation. Several new clinical trials have emerged since the previous meta‐analysis conducted in 2020. We conducted this updated meta‐analysis to assess clinical efficacy of lubiprostone in these patients.</p><h3>Methods</h3><p dir="ltr">A systematic search was conducted on MEDLINE, Cochrane, and Scopus. Randomized controlled trials published between July 2019 and June 2024 were selected. Cochrane's RoB 2 tool was used to assess the risk of bias. A meta‐analysis was performed and findings were presented using forest plots.</p><h3>Results</h3><p dir="ltr">A total of 14 studies, comprising 4550 patients, were included in the review. Only 12 studies were pooled in the meta‐analysis. Lubiprostone was associated with greater spontaneous bowel movements (SBM) per week (RR 1.454, 95% CI 1.193–1.771) and SBM within 24 h (RR 1.790, 95% CI 1.491–2.150) in patients with chronic idiopathic constipation (CIC). However, it was not associated with abdominal pain in either arm (RR 1.415, 95% CI 0.873–2.294). In opioid‐induced constipation (OIC), lubiprostone increased SBM within 24 h (RR 1.277, 95% CI 1.105–1.475) but did not significantly affect abdominal pain (RR 4.321, 95% CI 0.624–29.941). Lubiprostone improved all selected SBM‐related and abdominal pain outcomes in patients with irritable bowel syndrome with constipation (IBS‐C).</p><h3>Conclusion</h3><p dir="ltr">Lubiprostone significantly improves all SBM‐related outcomes. Owing to its good safety and efficacy profile, lubiprostone can be used in the combination regimens for management of CIC, IBS‐C, and OIC.</p><h2>Other Information</h2><p dir="ltr">Published in: JGH Open<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/jgh3.70070" target="_blank">https://dx.doi.org/10.1002/jgh3.70070</a></p>2025-01-15T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1002/jgh3.70070https://figshare.com/articles/journal_contribution/The_Efficacy_of_Lubiprostone_in_Patients_of_Constipation_An_Updated_Systematic_Review_and_Meta_Analysis/30173347CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/301733472025-01-15T09:00:00Z
spellingShingle The Efficacy of Lubiprostone in Patients of Constipation: An Updated Systematic Review and Meta‐Analysis
Umar Akram (20151411)
Biomedical and clinical sciences
Clinical sciences
Pharmacology and pharmaceutical sciences
chronic idiopathic constipation
constipation
irritable bowel syndrome
lubiprostone
opioid induced constipation
status_str publishedVersion
title The Efficacy of Lubiprostone in Patients of Constipation: An Updated Systematic Review and Meta‐Analysis
title_full The Efficacy of Lubiprostone in Patients of Constipation: An Updated Systematic Review and Meta‐Analysis
title_fullStr The Efficacy of Lubiprostone in Patients of Constipation: An Updated Systematic Review and Meta‐Analysis
title_full_unstemmed The Efficacy of Lubiprostone in Patients of Constipation: An Updated Systematic Review and Meta‐Analysis
title_short The Efficacy of Lubiprostone in Patients of Constipation: An Updated Systematic Review and Meta‐Analysis
title_sort The Efficacy of Lubiprostone in Patients of Constipation: An Updated Systematic Review and Meta‐Analysis
topic Biomedical and clinical sciences
Clinical sciences
Pharmacology and pharmaceutical sciences
chronic idiopathic constipation
constipation
irritable bowel syndrome
lubiprostone
opioid induced constipation